FY2024 Earnings Forecast for Nevro Issued By William Blair

Nevro Corp. (NYSE:NVRO) – Analysts at William Blair upped their FY2024 earnings estimates for shares of Nevro in a report issued on Tuesday, November 12th. William Blair analyst B. Vazquez now expects that the medical equipment provider will post earnings per share of ($2.59) for the year, up from their previous forecast of ($2.90). The consensus estimate for Nevro’s current full-year earnings is ($2.60) per share. William Blair also issued estimates for Nevro’s Q4 2024 earnings at ($0.95) EPS, Q1 2025 earnings at ($0.97) EPS, Q2 2025 earnings at ($0.85) EPS, Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.55) EPS, FY2025 earnings at ($2.85) EPS, Q1 2026 earnings at ($0.78) EPS, Q2 2026 earnings at ($0.59) EPS and Q3 2026 earnings at ($0.63) EPS.

NVRO has been the subject of a number of other reports. Wolfe Research raised shares of Nevro from an “underperform” rating to a “peer perform” rating in a report on Thursday, August 8th. Canaccord Genuity Group decreased their price objective on Nevro from $8.00 to $7.00 and set a “hold” rating on the stock in a report on Tuesday. Truist Financial dropped their target price on Nevro from $10.00 to $5.50 and set a “hold” rating for the company in a report on Thursday, August 8th. StockNews.com raised Nevro from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Finally, JMP Securities reiterated a “market perform” rating on shares of Nevro in a research note on Tuesday. Three investment analysts have rated the stock with a sell rating and twelve have issued a hold rating to the stock. According to data from MarketBeat.com, Nevro has an average rating of “Hold” and a consensus price target of $9.10.

Nevro Stock Down 8.7 %

Shares of NVRO stock opened at $4.07 on Thursday. Nevro has a one year low of $4.00 and a one year high of $22.64. The company has a debt-to-equity ratio of 0.66, a current ratio of 4.77 and a quick ratio of 3.53. The stock has a fifty day moving average price of $5.21 and a 200 day moving average price of $7.42. The stock has a market cap of $151.56 million, a P/E ratio of -2.14 and a beta of 0.93.

Nevro (NYSE:NVRO) last posted its quarterly earnings results on Monday, November 11th. The medical equipment provider reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.40. Nevro had a negative return on equity of 23.35% and a negative net margin of 16.54%. The firm had revenue of $96.60 million during the quarter, compared to analysts’ expectations of $93.09 million. During the same quarter in the prior year, the firm posted ($0.65) EPS. The company’s revenue for the quarter was down 7.0% on a year-over-year basis.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. PDT Partners LLC acquired a new stake in shares of Nevro in the 3rd quarter valued at $99,000. Engaged Capital LLC raised its holdings in Nevro by 29.5% during the 3rd quarter. Engaged Capital LLC now owns 2,442,956 shares of the medical equipment provider’s stock worth $13,656,000 after purchasing an additional 557,000 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Nevro by 130.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,000,000 shares of the medical equipment provider’s stock valued at $5,590,000 after purchasing an additional 566,462 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Nevro by 171.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 135,145 shares of the medical equipment provider’s stock valued at $755,000 after purchasing an additional 85,324 shares during the last quarter. Finally, Quantbot Technologies LP grew its position in shares of Nevro by 1,290.4% during the 3rd quarter. Quantbot Technologies LP now owns 14,418 shares of the medical equipment provider’s stock worth $81,000 after buying an additional 13,381 shares during the period. Institutional investors own 95.52% of the company’s stock.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.